Literature DB >> 28137898

Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy.

Jens Steen Olesen1, Mikala Wang2, Christian Wejse1,3.   

Abstract

A 66-year-old multimorbid man with rheumatoid arthritis developed an infection after a steroid injection in the hand. Mycobacterium chelonae was cultured 1-month after presentation. In the mean time, his third finger had been amputated. Further treatment was based on preliminary susceptibility testing and the American Thoracic Society guidelines. No regression of the infection was observed before the addition of linezolid (600 mg×1/day) to a combination antimicrobial therapy also consisting of clarithromycin (500 mg×2/day) and moxifloxacin (400 mg×1/day), even though two methods of susceptibility testing, the E-test and broth microdilution, had shown susceptibility to other antimicrobial drugs. The healing was complete 12 months after presentation. There were no serious side effects observed with the use of linezolid in reduced dosage of 600 mg×1/day for a duration of 9 months. 2017 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28137898      PMCID: PMC5293961          DOI: 10.1136/bcr-2016-217257

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  36 in total

1.  The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment.

Authors:  M L Heginbothom
Journal:  Int J Tuberc Lung Dis       Date:  2001-06       Impact factor: 2.373

2.  [Disseminated cutaneous infection by Mycobacterium chelonae after botulinic toxin injection in an immunosuppressed patient].

Authors:  Germán Latorre-González; Mercedes García-García; María Martínez Martínez-Colubi; Juncal Pérez-Somarriba Moreno
Journal:  Med Clin (Barc)       Date:  2005-10-01       Impact factor: 1.725

3.  [Contamination of endoscopes and endoscope washers by atypical mycobacteria].

Authors:  K Negayama; S Terada; H Kiuchi; Y Inaoka; K Kawanishi
Journal:  Kansenshogaku Zasshi       Date:  1992-03

4.  Detection and identification of mycobacteria in the Lisbon water distribution system.

Authors:  R Santos; F Oliveira; J Fernandes; S Gonçalves; F Macieira; M Cadete
Journal:  Water Sci Technol       Date:  2005       Impact factor: 1.915

5.  Proposal of Mycobacterium peregrinum sp. nov., nom. rev., and elevation of Mycobacterium chelonae subsp. abscessus (Kubica et al.) to species status: Mycobacterium abscessus comb. nov.

Authors:  S Kusunoki; T Ezaki
Journal:  Int J Syst Bacteriol       Date:  1992-04

6.  Successful treatment of disseminated Mycobacterium chelonae infection with linezolid.

Authors:  B A Brown-Elliott; R J Wallace; R Blinkhorn; C J Crist; L B Mann
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

Review 7.  Mycobacteria in drinking water distribution systems: ecology and significance for human health.

Authors:  Mario J M Vaerewijck; Geert Huys; Juan Carlos Palomino; Jean Swings; Françoise Portaels
Journal:  FEMS Microbiol Rev       Date:  2005-02-19       Impact factor: 16.408

8.  Occurrence and characterization of multiple novel genotypes of Mycobacterium immunogenum and Mycobacterium chelonae in metalworking fluids.

Authors:  Izhar U H Khan; Suresh B Selvaraju; Jagjit S Yadav
Journal:  FEMS Microbiol Ecol       Date:  2005-11-01       Impact factor: 4.194

9.  Primary cutaneous cryptococcosis: a distinct clinical entity.

Authors:  Ségolène Neuville; Françoise Dromer; Odile Morin; Bertrand Dupont; Olivier Ronin; Olivier Lortholary
Journal:  Clin Infect Dis       Date:  2003-01-17       Impact factor: 9.079

10.  Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin.

Authors:  R J Wallace; B A Brown; G O Onyi
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.